Abstract
Botulinum neurotoxins (BoNTs) are endopeptidases that target motor neurons and block acetylcholine neurotransmitter release. This action results in the muscle paralysis that defines the disease botulism. To date, there are no FDA-approved therapeutics to treat BoNT-mediated paralysis after intoxication of the motor neuron. Importantly, the rationale for pursuing treatments to counter these toxins is driven by their potential misuse. Current drug discovery efforts have mainly focused on small molecules, peptides, and peptidomimetics that can directly and competitively inhibit BoNT light chain proteolytic activity. Although this is a rational approach, direct inhibition of the Zn2+ metalloprotease activity has been elusive as demonstrated by the dearth of candidates undergoing clinical evaluation. Therefore, broadening the scope of viable targets beyond that of active site protease inhibitors represents an additional strategy that could move the field closer to the clinic. Here we review the rationale, and discuss the outcomes of earlier approaches and highlight potential new targets for BoNT inhibition. These include BoNT uptake and processing inhibitors, enzymatic inhibitors, and modulators of neuronal processes associated with toxin clearance, neurotransmitter potentiation, and other pathways geared towards neuronal recovery and repair.
Keywords: Botulinum neurotoxin, botulism, drug discovery, neuronal-based therapeutics, small molecule botulinum inhibitors, SNARE.
Current Topics in Medicinal Chemistry
Title:Recent Advances in Botulinum Neurotoxin Inhibitor Development
Volume: 14 Issue: 18
Author(s): Erkan Kiris, James C. Burnett, Christopher D. Kane and Sina Bavari
Affiliation:
Keywords: Botulinum neurotoxin, botulism, drug discovery, neuronal-based therapeutics, small molecule botulinum inhibitors, SNARE.
Abstract: Botulinum neurotoxins (BoNTs) are endopeptidases that target motor neurons and block acetylcholine neurotransmitter release. This action results in the muscle paralysis that defines the disease botulism. To date, there are no FDA-approved therapeutics to treat BoNT-mediated paralysis after intoxication of the motor neuron. Importantly, the rationale for pursuing treatments to counter these toxins is driven by their potential misuse. Current drug discovery efforts have mainly focused on small molecules, peptides, and peptidomimetics that can directly and competitively inhibit BoNT light chain proteolytic activity. Although this is a rational approach, direct inhibition of the Zn2+ metalloprotease activity has been elusive as demonstrated by the dearth of candidates undergoing clinical evaluation. Therefore, broadening the scope of viable targets beyond that of active site protease inhibitors represents an additional strategy that could move the field closer to the clinic. Here we review the rationale, and discuss the outcomes of earlier approaches and highlight potential new targets for BoNT inhibition. These include BoNT uptake and processing inhibitors, enzymatic inhibitors, and modulators of neuronal processes associated with toxin clearance, neurotransmitter potentiation, and other pathways geared towards neuronal recovery and repair.
Export Options
About this article
Cite this article as:
Kiris Erkan, Burnett C. James, Kane D. Christopher and Bavari Sina, Recent Advances in Botulinum Neurotoxin Inhibitor Development, Current Topics in Medicinal Chemistry 2014; 14 (18) . https://dx.doi.org/10.2174/1568026614666141022093350
DOI https://dx.doi.org/10.2174/1568026614666141022093350 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Chromogranins and Other Statins in Homeostasis: An Explanation of the Precise Regulation of Glucose and Ionised Calcium in the Blood; An Overview
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Selenium: A Cure for Autoimmune Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets Age-Specific Impairment of Morris Water Maze Performance Following Neonatal Exposure to Magnetic Resonance Image in Rats
Current Neurovascular Research Current and Near-Future Treatment of Alzheimer’s Disease
Current Neuropharmacology Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design The Profile of Angiogenic Factors in Vitreous Humor of the Patients with Proliferative Diabetic Retinopathy
Current Molecular Medicine Human postnatal Mesenchymal Stem Cell Derived Islets as a Model for Diabetes Research
Current Diabetes Reviews Looking for New Inhibitors for the Epidermal Growth Factor Receptor
Current Topics in Medicinal Chemistry The Brain Galanin Receptors: Targets for Novel Antidepressant Drugs
CNS & Neurological Disorders - Drug Targets Activated Immune System and Inflammation in Healthy Ageing: Relevance for Tryptophan and Neopterin Metabolism
Current Pharmaceutical Design Systematic Review Investigating Multi-disciplinary Team Approaches to Screening and Early Diagnosis of Dementia in Primary Care – What are the Positive and Negative Effects and Who Should Deliver It?
Current Alzheimer Research Prediabetic Dysglycemia: Call for Action
Current Diabetes Reviews Phyto-glycosides as Therapeutic Target in the Treatment of Diabetes
Mini-Reviews in Medicinal Chemistry Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors
Current Pharmaceutical Biotechnology Adipokines and Adipocyte Targets in the Future Management of Obesity and the Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Novel Vaginal Drug Delivery Systems: A Review
Current Drug Therapy Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer?
Current Medical Imaging Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Fatty Acid Intakes and Coronary Heart Disease Mortality in Japan: NIPPON DATA90, 1990-2005
Current Nutrition & Food Science